Skip to main content
Clinical Trials/NCT00003950
NCT00003950
Completed
Phase 2

A Phase II Trial of Irinotecan (CPT-11) and Cyclosporine in Patients With 5-FU Refractory Advanced Colorectal Cancer

University of Chicago10 sites in 1 country16 target enrollmentJanuary 2000

Overview

Phase
Phase 2
Intervention
cyclosporine
Conditions
Colorectal Cancer
Sponsor
University of Chicago
Enrollment
16
Locations
10
Primary Endpoint
Reduction in occurrences of severe diarrhea due to CPT-11 administration
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cyclosporine may relieve the diarrhea caused by irinotecan.

PURPOSE: Phase II trial to study the effectiveness of irinotecan and cyclosporine in treating patients who have metastatic, advanced, or locally recurrent colorectal cancer that has not responded to fluorouracil.

Detailed Description

OBJECTIVES: I. Determine the response rate of patients with metastatic, advanced, or locally recurrent fluorouracil refractory adenocarcinoma of the colon or rectum treated with irinotecan and cyclosporine. II. Determine antitumor activity, safety, tolerance, and toxicity of this combination treatment in these patients. OUTLINE: This is a multicenter study. Patients receive cyclosporine IV over 6 hours and irinotecan IV over 90 minutes weekly for 4 weeks. Courses repeat every 6 weeks. Patients receive at least 2 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 15-45 patients will be accrued for this study over 14 months.

Registry
clinicaltrials.gov
Start Date
January 2000
End Date
January 2005
Last Updated
12 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

CPT-11 with Cyclosporine

Each cycle lasts 6 weeks. Administration of cyclosporine and CPT-11 weekly for 4 weeks followed by a 2 week 'rest' period with no drug given. Cyclosporine is given by IV infusion at a dose of 5 mg/kg. CPT-11 is given by IV infusion at a dose of 60 mg/m2.

Intervention: cyclosporine

CPT-11 with Cyclosporine

Each cycle lasts 6 weeks. Administration of cyclosporine and CPT-11 weekly for 4 weeks followed by a 2 week 'rest' period with no drug given. Cyclosporine is given by IV infusion at a dose of 5 mg/kg. CPT-11 is given by IV infusion at a dose of 60 mg/m2.

Intervention: CPT-11

Outcomes

Primary Outcomes

Reduction in occurrences of severe diarrhea due to CPT-11 administration

Time Frame: 12 weeks

Study Sites (10)

Loading locations...

Similar Trials